ASH 2024 – Merck treads a fine line in ROR1
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
Investors don't buy Lyell's solid tumour Car-T success
The ROR1 data are sketchy, and lung toxicity clouds prospects.
Pfizer hopes not to get stung
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
